Novo Nordisk

News

Sanofi, Lilly and Novo make cases for diabetes drugs at ADA

The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for

Views & Analysis

Beyond glucose in type 2 diabetes: how Novo Nordisk is looki...

After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on putting patients at the centre of the company and providing medical lead

News

Sanofi/Regeneron skin cancer drug among flurry of decisions ...

A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.

News

FDA approves PureTech's obesity device Plenity

The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.

News

Gilead and Novo Nordisk collaborate for NASH trial

Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) combining compounds from each of their pipelines, including Novo

News

Novo prevents Teva's Victoza rival launch until 2023

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Sanofi, Lilly and Novo make cases for diabetes drugs at ADA

Beyond glucose in type 2 diabetes: how Novo Nordisk is looki...

Sanofi/Regeneron skin cancer drug among flurry of decisions ...

FDA approves PureTech's obesity device Plenity

Gilead and Novo Nordisk collaborate for NASH trial

Novo prevents Teva's Victoza rival launch until 2023

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

Novo Nordisk

Editor's Picks